trial

Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal

NCTId NCT00314613
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Terminated
Enrollment 30 (estimated)
Sponsored by Duke University
Primary completion 2006-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Terminated
Enrollment
30 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
—
Masking
None
Start
2006-04
Primary completion
2006-12
Eligibility
ALL · 18 Years · 40 Years

Interventions & indications

Drugs
Risperidone

Sponsors

Duke UniversityLead Sponsor
Janssen, L.P. - Investigator Initiated Studies ProgramCollaborator

Investigators

2
William H Wilson, PhDPrincipal Investigator
Joseph P. McEvoy, MDPrincipal Investigator

Sites

2 total
Butner, United StatesDurham, United States

Facts & assertions

4 sourced
Enrollment
30
Phase
PHASE4
Primary Completion Date
2006-12
Status
TERMINATED
relationships
The graph out of here
drug
Risperidone
drug
lead_sponsor
Duke University
company
collaborator
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication
investigator
William H Wilson, PhD
person
Joseph P. McEvoy, MD
person